HighTide Therapeutics Inc., a globally focused clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholang

Dr. Liping Liu, Founder & CEO of HighTide will present at the 25th Annual Future Leaders In The Biotech Industry on 23rd March 2018 in New York City. Dr. Liu will highlight HighTide’s product pipeline and development strategy. The...

HTD1801, one of HighTide’s lead candidates, awarded a grant in China as the ‘National Science and Technology Major Project’ for ‘New Drug Research and Development’ in November 2017....

The HTD4010 project has completed Phase I clinical trials in Australia in recent days, and the test has reached the expected target. The trial data will be used to support the start of phase 2 clinical trials in the United...

The HTD4010 has been registered by the Australian Drug Administration and is about to enter Phase I clinical trials in Australia. Clinical data will be...